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examined so that discussions about best care can appro-
priately represent the multiplicity of perspectives.
ThecurrentdialoguedescribingflawsintheCKDstaging
systemandtheneedtomodifytheclassificationsystemmay
or may not be useful in advancing the field or caring for
patients [2,3]. Increasing the precision of the predictability
ofprogressionatanygivenstagebyaddingparametersmay
be valuable but should not change the fundamental premise
of the staging system [14]. Age-adjusted values for eGFR
willnotaddresstheissuesappropriately,norwilltheylikely
lead to a change in current knowledge or outcomes.
The elderly do have CKD, to a greater proportion than
do their younger counterparts. The natural history of the
conditionisdifferent,notthediseaseitself.Thecareofthese
patients therefore is likely not the same as that of younger
age groups, but we are still far from understanding how to
optimize the care of these patients. Identifying progressors,
irrespectiveofage,isafirststepinalongroadofdiscovery.
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Three articles published in the New England Journal of
Medicine at the beginning of 2008 demonstrated that the
induction or development of mixed chimerism in kidney
or liver transplant recipients can lead to long-term donor
specific tolerance following transplantation, irrespective of
whether the chimerism is sustained or not [1–3].
Chimerism occurs when foreign (donor) haematopoietic
cells are present in an individual. Complete chimerism
indicates that all haematopoietic cells (100%) are derived
from a donor stem cell inoculum (for example, following
myeloablation and transplantation of donor haematopoietic
cells), whereas in mixed chimerism donor cells of multiple
lineages constitute a varying part of the total haematopoi-
etic pool. When the presence of donor cells occurs at
levels below that detectable by flow cytometry (<1%),
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and can only be detected by more sensitive methods such
as polymerase chain reaction (PCR), it is referred to as
microchimerism [4].
Individualswhohavecompletechimerismaftermyeloab-
lative therapy and bone marrow transplantation subse-
quently accept solid organ allografts from the same donor
[5]. The complete replacement of host bone marrow with
that from an allogeneic donor results in the tolerance to
the alloantigens of the bone marrow donor. However, this
approach requires complete myeloablation that is associ-
ated with substantial morbidity and mortality. While this
is essential in patients with haematological malignancy to
ensure that all tumour cells are eliminated before bone
marrow transplantation, it would not be justified as a treat-
mentstrategyintransplantrecipientswithotherwisenormal
bonemarrow.Furthermore,bonemarrowtransplant(BMT)
across HLA barriers carries a substantial risk of graft-
versus-host disease (GVHD). In contrast, mixed chimerism
can be established using non-myeloablative conditioning
regimens and is associated with a reduced susceptibil-
ity to GVHD [6], whilst maintaining improved immuno-
competence [7]. Consequently, there has been considerable
research to develop protocols that permit mixed chimerism
following transplantation.
The persistence of donor-derived haematopoietic cells
has been suggested to modulate immune responsiveness
to donor alloantigens facilitating the development of
tolerance. Interestingly, the persistence, albeit at low levels,
of maternal cells in their off-spring have been reported and
implicated in the acquisition of immunological tolerance to
non-inherited maternal antigens [8,9].Microchimerismhas
also been detected in transplant recipients with long-term
surviving allografts [4,10,11]. However, direct evidence
of immunomodulation that leads to tolerance by the per-
sistence of low levels of chimerism in vivo is inconsistent.
One study showed that one-third of patients with long-term
graft survival had microchimerism [12], whereas in
others microchimerism could still be detected in patients
experiencing allograft rejection [13,14] with the level of
chimerism fluctuating with time [14]. Thus, there does
not appear to be a clear correlation between the detection
of microchimerism and clinical outcome, i.e. rejection or
tolerance.
To achieve tolerance, both pre-existing mature donor-
reactive T cells and developing donor-reactive T cells need
to be eliminated or inactivated in a sustained manner. To
achievethelatter,experimentalmodelsofmixedchimerism
employ total body irradiation (TBI) [15], T cell-depleting
antibodies, cytotoxic drugs, [16,17] or the induction of pe-
ripheral clonal deletion using costimulatory blockade [18].
After rendering peripheral donor-reactive T cells ineffec-
tive, central tolerance in mixed chimerism is most likely
achieved when donor stem cells engraft, producing cells
of multiple haematopoietic lineages including haematopoi-
etic progenitor cells that seed the thymus. The progenitor
cells that persist in the thymus can develop into special-
ized thymic dendritic cells [19] that can induce deletion of
antigen-specific T cells (clonal deletion). Thus, in mixed
chimerism, both host and donor haematopoietic cells medi-
ate intrathymic deletion of host and donor-reactive T cells
[20]. This renders the host tolerant to host and donor anti-
gens, as long as the donor haematopoietic stem cells persist
in the bone marrow.
Early work demonstrated that after TBI, mice reconsti-
tuted with a mixture of recipient and donor bone marrow
develop mixed chimerism and robust tolerance to donor
skin grafts [15]. Subsequent studies improved this pro-
tocol by reducing the toxicity of host conditioning, us-
ing leukocyte-depleting agents, such as anti-thymocyte
or lymphocyte globulin (ATG or ALG) [21], and subse-
quently depleting anti-CD4 and anti-CD8 monoclonal an-
tibodies (mAb) [16] or by co-stimulation blockade prior to
a non-myeloablative dose of TBI. Immunocompetence is
demonstrated by the fact that these mice are able to reject
third-party grafts [16], whereas protocols that induce full
chimerism also induce a degree of immuno-incompetence
[23]. Interestingly, these protocols typically produce indef-
inite mixed chimerism in mice, whereas in non-human pri-
mates (NHP) mixed chimerism is sustained for only a few
weeks [24], yet long-term graft survival is also maintained.
These promising animal results posed an interesting
ethical dilemma, which delayed the translation of mixed
chimerism strategies into human studies: does the potential
benefit of long-term graft survival without immunosup-
pression outweigh the risk of bone marrow ablative ther-
apy in patients with end-stage renal disease (ESRD) and
normal bone marrow? This question remained unanswered
until 1998, when a trial began in patients with renal failure
due to myeloma, who therefore required both bone marrow
and renal transplants. A modification of a tolerogenic NHP
protocolwasemployed,inwhichpatientsunderwentthymic
irradiation together with ATG, but with cyclophosphamide
(instead of TBI, which was used in NHP) prior to simul-
taneous HLA-matched bone marrow and renal transplan-
tation. Six such transplants have been performed to date,
withallpatientsacceptingtheirgraftslong-term[25].Inter-
estingly, three patients lost detectable chimerism but main-
tained graft function without immunosuppression or rejec-
tion episodes for up to 7 years [25]. This loss of chimerism
was in marked contrast to what had been observed in both
small and large animal studies.
Importantly, this approach has since been extended to
patients with ESRD but without bone marrow disease and
to HLA single haplotype-mismatched donors [2]. Protocol
modifications were required to enable non-myeloablative
conditioning to be used successfully in patients who were
receiving transplants from HLA-mismatched donors, that
included replacing ATG with anti-CD2 mAb together with
the addition of anti-CD20 therapy to reduce the risk of hu-
moral rejection, as one patient in the series of five lost their
graft due to irreversible humoral rejection. The remain-
ing four patients also suffered a rejection-like capillary-
like syndrome. However, all episodes responded to corti-
costeroids and withdrawal of immunosuppression was still
successful, demonstrated by excellent renal function for
between 2 and 5 years post-transplantation to date, fol-
lowing withdrawal of all immunosuppressive therapy with
evidence for immunologic recovery in vivo and in vitro [2].
Despite the exciting potential of these results, sev-
eral important questions remain unanswered. Primarily,
the underlying mechanism remains unknown, as leuko-
cyte chimerism was only demonstrable for 3 weeks. This1728 Nephrol Dial Transplant (2009) 24: Editorial Comments
does not exclude microchimerism as a possible mecha-
nism, as the study only analysed peripheral blood sam-
ples.Furthermore,althoughhighlevelsofFoxp3messenger
RNA were found in allograft biopsies, and donor-specific
unresponsiveness was observed in vitro, no direct evidence
was provided of suppressive activity attributable to regula-
tory T cells.
The second paper in the series reported persistent mixed
chimerism in one patient, from a series with multiple
myeloma and ESRD, who received a combined renal trans-
plant and HLA-matched donor haematopoietic cells, fol-
lowing a conditioning regime of total lymphoid irradia-
tion (TLI), ATG and mycophenolate mofetil for 1 month
post-transplantation [3]. Allograft function has been nor-
malinthepatientwithpersistentmixedchimerismformore
than 2 years since discontinuation of immunosuppression,
with no episodes of rejection. Analysis of this patient’s T
cells after transplantation demonstrated that naive CD8+
T cells repopulated the periphery faster than na¨ ıve CD4+
T cells. This was thought to be due to peripheral expan-
sion rather than thymic generation of new T cells. Addi-
tional analysis indicated that donor lymphocytes present in
the recipient were of thymic origin, suggesting a central
deletion mechanism [3]. This study supports earlier work
demonstrating that pre-transplant TLI can induce mixed
chimerism and immune tolerance to cadaveric renal allo-
grafts [26] whereas post-transplant TLI produces transient
microchimerism and acute rejection following withdrawal
of immunosuppression [27]. The authors suggest the per-
sistent chimerism in this patient was due to engraftment
of donor stem cells (as outlined earlier). This raises an in-
teresting comparison with the previously described study
from Kawai and colleagues, as stem cells were thought
to contribute to chimerism in both cases, but chimerism
was not maintained in the former study, yet both studies
demonstrated excellent graft function after withdrawal of
immunosuppression.Clearly,thereisastrongneedformore
basic scientific research to dissect the differences in these
protocols, and determine the role of chimerism in tolerance
induction.
Interestingly, in a third article in the same issue of the
New England Journal of Medicine [22], a unique report
demonstrates how the evolution of chimerism may be af-
fected by immunosuppression: a 9-year-old girl developed
acute fulminant hepatitis after a nonspecific viral illness,
and underwent liver transplantation from a deceased male
donor. Nine months after transplantation, her peripheral
blood had converted to the HLA of the donor, indicating
the development of chimerism by engraftment of recipi-
ent marrow by passenger haematopoietic stem cells from
the transplanted liver. One month later, the patient devel-
oped steroid-resistant severe intravascular haemolysis with
haemoglobinuriaandtransientrenalinsufficiency.Haemol-
ysis was thought to be due to residual recipient peripheral
B cells (of which 98% were donor & 2% were host de-
rived), as marrow analysis indicated that all B cells were
of donor origin (XY). Immunosuppression was withdrawn,
which permitted completion of engraftment and resolution
of the anaemia. In this patient, the profound lymphopenia
at presentation and in the subsequent months after trans-
plantation, plus the immunosuppressive effects of drugs
such as tacrolimus, azathioprine and ganciclovir, may have
contributed to the engraftment of donor haematopoietic
stem cells. The cause of hepatitis and profound lymphope-
nia remains unknown, although various hepatotrophic
viruses can cause both these symptoms [28]. Despite the
fortuitous nature of the outcome, this study provides ex-
citing evidence linking preoperative lymphodepletion with
a successful long-term graft outcome. Whether acciden-
tal or intentional, preoperative lymphodepletion links all
three articles described above. Starzl has suggested that
this process permits reciprocal clonal deletion of donor and
recipient immunocompetent cells after engraftment, which
facilitates a tolerant state [29]. Any imbalance in this pro-
cess will produce either graft versus host disease, or host
versus graft effects (rejection). However, the significance
of this mechanism is not fully understood, because current
immunosuppressive regimens are likely to interfere with
the process of clonal deletion.
Taken together, these three reports show that proto-
cols which induce mixed chimerism can lead to long-term
donor-specific tolerance following renal transplantation,
whetherchimerismissustainedornot.Althoughthesestud-
ies provide a fascinating insight into the potential role of
chimerism in humans, data remain sparse in comparison
to animal studies. Notably, recent animal data indicate that
donor tissue rejection by chimeras can still occur, presum-
ably because some tissue antigens are not expressed on
donor haematopoietic cells [30] or that other mechanisms
associated with the function of the adaptive immune sys-
tem may play a role [31]. Such processes must be borne
in mind when we consider the application of strategies to
induce mixed chimerism in humans. However, although the
mechanisms remain incompletely understood, the potential
therapeutic application of these approaches is promising.
The experience learned from the adverse events in the hu-
manstudieswedescribedshouldenablethedevelopmentof
more robust protocols, which is vital before such protocols
are more widely employed.
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